Screen Reader Mode Icon
Welcome to PIR International’s 2022 Biotech Board & Executive Remuneration Study. An independent and exclusive study which focuses directly on growth stage Biotech board members and executives to help bridge a clear gap in available data on key aspects of compensation, equity distribution, participation and diversity amongst leading European and UK Biotechs.
By participating in this confidential and anonymous study, participants are granted access to the finalised in-depth report, with an anticipated release Autumn 2022. The report will reveal key trends and grant actionable insights for both board and executive level participants on a personal career level but also importantly enable application to their organisations.
PIR International’s 2022 Biotech Board & Executive Remuneration Study is a data-driven resource that empowers executives, investors and the boardroom with the insights they need to improve board governance, top-level business decisions and truly excel. This strictly independent, anonymised and confidential remuneration study is designed to leverage participation from the entire European and UK biotech ecosystem that will give the very latest data to drive important insights for all decision-makers in this sector.
All data is collected in the strictest confidence and is subject to EU/UK GDPR regulations.

Confidentiality and Privacy Statement
All data in the 2022 Biotech Board & Executive Remuneration Study is confidential and will be automatically anonymized by the survey software, validated, and stored in line with PIR International’s GDPR policy which conforms to EU and UK GDPR legislation, please see our website for the full policy.  The sole purpose of the data is to provide accuracy and integrity to the survey. No personal data will be stored or shared with a third party.  The anonymized data will be compiled into a survey report that will be available by request.